- Email: [email protected]
A handbook on drug and alcohol abuse; the biomedical aspects. 3rd edition
404
Book Reviews
great deal of information there is not “information over load”. The chapters deal with (1) scientific basis; Is the drug getting into the patient? Is the drug getting to its site of action? Is the drug producing the required pharmacological effect? Is the pharmacological effect being translated into the appropriate therapeutic effect? Practical applications; monitoring drug therapy; pharmacogenetics; adverse reactions; drug interactions; treatment of the young and the elderly; reproduction; patient compliance; placebos; regulatory authorities; clinical trials. (2) Practical prescribing; principles; how to write a prescription; sources of drug information. (3) Drug therapy; infectious diseases; cardiovascular disorders; respiratory; gastro-intestinal, hepatic and bilary; kidney, renal, urinary tract and prostate; endocrine and metabolism; blood; bones and joint; neurological; psychiatric; pain; anaesthesia; drug dependence and abuse; management of poisoning; cancer chemotherapy; immunosuppression, allergies, connective tissue. (4) Pharmacopoeia. If this book is purchased. it will be read!
A Handbook on Drug and AIcohol Abuse; the Biomedical Aspects. 3rd Edition-Bv G. WINCER. F. G. HOFMANN and J. H. WOODS.219~~. 1992. Oxford University Press. Oxford. E40. In 1982 it was estimated that 66% of Americans had used an illicit drug before they graduated from high school. It is also estimated (1990) that there are 1.6 million users of cocaine in the U.S.A.; that 1% of all Americans have used heroin at least once and that there are 500,000 current users of heroin. This text deals with; why people abuse drugs; tobacco and nicotine; opioid drugs; alcohol, barbiturates and benzodiazepines; volatile solvents; hallucinogens, phencyclidines, LSD; marihuana and hashish; amphetamines, MDMA (ecstasy) caffeine; cocaine; medical diagnosis of drug abuse; management of selected problems (overdose, withdrawal, treatment of new born infants); drug abuse and the law. The use of each drug is described together with its social and clinical effects. Process Validation. 2nd Edition-Edited by I. R. BERRYand R. A. NASH. 597 pp. 1993. Marcel Dekker, New York. $125.
6th Edition-Edited by H. P. and F. W. O’GRADY. 561 DD. 1992. Churchill Livingstone, Edinburgh, $149.95.
Pharmaceutical
This major text has been completely revised and brought up to date. The chapters deal with (1) agents; aminoglycosides and aminocyclitols; antifungals; antimycobacteria; antivirals; beta lactams; cephalosporins; chloramphenicol and thiamphenicol; coumarins; cycloserine; diamidines; diaminopyridines; fosfomycin and fosmidomycin; fusidanes; hexamine; lincosamides; macrolides; mupirocin; nitrofurans; nitroimidazoles; penicillins; peptides; quinolones; rifamycins; sulphonamides; tetracychnes; mode of action; bacterial resistance. (2) Treatment; general principles; immunocomprised host; infective endocarditis; septicaemia; respiratory tract; meningitis; alimentary tract; bacterial skin; urinary tract; obstetrics; sexually transmitted diseases; eye; tuberculosis and leprosy; renal failure; chemoprophylaxis. In dealing with each drug the chapter gives its structure; antimicrobial activity; acquired resistance; pharmacokinetics; toxicity and side effects; clinical use; preparations and dosage; references. A very useful book.
The previous edition came out 8 years ago and in 1987 the FDA produced their Guidelines on the general principles of process validation. There is also the development of current good manufacturing practice regulations. This new edition reflects the care that has to be taken over these new requirements. It deals with the validation (V) of; sterile products; solid dosage forms; quality assurance; prospective process V; retrospective process V; V of water systems; cleaning V; equipment V; process V of raw materials; V of analytical methods; V of computer systems; V of lyophilized products; V of inhalation aerosols; use of quality control charts; multivariate graphical analysis; new trends in process V; V terminology. When billions of doses of drugs are consumed by the public, the validation of the procedures producing these drugs has to be of a very high standard otherwise the mortician gets the patient and the lawyers get the manufacturer.
Antibiotic and Chemotherapy. LAMBERT
New Approaches in Cancer Pharmacology; Drug Design and Development-Edited by P. WORKMAN. 103 pp. 1992. Springer, Berlin. DM 102. With the increase in understanding the basic biology of cell reproduction, has come a greater understanding of the control methods. This is reflected in the present volume which deals with; sequence and gene specific drugs; antisense and antigene oligonucleotides targeted to oncogenes; biological and gene therapies; membrane and signal transduction targets; novel anti-endocrine agents; bioreductive drugs [hypoxia]; therapeutic drug monitoring and dose optimization in oncology; current strategies of anticancer drug discovery, i.e. targeting onto cell membrane; growth factors and receptors; signal tranduction proteins; oncogenes; cell cycle regulators; extrachromosomal DNA; hypoxia; tumour cell differentiation; tumour vasculature; topiosomerase I; mitochondria; microtubules.
New Drug Approval Process. 2nd Edition-Edited by R. A. GUARINO.469~~. 1993. Marcel Dekker, New York. $150 ($65 if 5 or more copies are bought for classroom use). This new edition has been revised and updated to reflect the current rules, regulations and guidelines of Title 21 of the Code of Federal Regulations. The topics dealt with are; non-clinical research evaluation; Investigational New Drug (IND) and clinical investigators brochure; clinical research protocols; clinical development of OTC drugs; statistical and data management collaboration in clinical research; biotechnology; image processing techniques applied to drug development; obligations of investigator, sponsor and monitor; management of clinical studies; adverse reactions and interactions of drugs; institution review boards, informed consent and auditing; new drug application (NDA); drug product labelling; drugs for life threatening diseases; abbreviated and supplemental new drug applications; the orphan drugs. This book should help the investigator through the administration minefields.
Book Reviews
great deal of information there is not “information over load”. The chapters deal with (1) scientific basis; Is the drug getting into the patient? Is the drug getting to its site of action? Is the drug producing the required pharmacological effect? Is the pharmacological effect being translated into the appropriate therapeutic effect? Practical applications; monitoring drug therapy; pharmacogenetics; adverse reactions; drug interactions; treatment of the young and the elderly; reproduction; patient compliance; placebos; regulatory authorities; clinical trials. (2) Practical prescribing; principles; how to write a prescription; sources of drug information. (3) Drug therapy; infectious diseases; cardiovascular disorders; respiratory; gastro-intestinal, hepatic and bilary; kidney, renal, urinary tract and prostate; endocrine and metabolism; blood; bones and joint; neurological; psychiatric; pain; anaesthesia; drug dependence and abuse; management of poisoning; cancer chemotherapy; immunosuppression, allergies, connective tissue. (4) Pharmacopoeia. If this book is purchased. it will be read!
A Handbook on Drug and AIcohol Abuse; the Biomedical Aspects. 3rd Edition-Bv G. WINCER. F. G. HOFMANN and J. H. WOODS.219~~. 1992. Oxford University Press. Oxford. E40. In 1982 it was estimated that 66% of Americans had used an illicit drug before they graduated from high school. It is also estimated (1990) that there are 1.6 million users of cocaine in the U.S.A.; that 1% of all Americans have used heroin at least once and that there are 500,000 current users of heroin. This text deals with; why people abuse drugs; tobacco and nicotine; opioid drugs; alcohol, barbiturates and benzodiazepines; volatile solvents; hallucinogens, phencyclidines, LSD; marihuana and hashish; amphetamines, MDMA (ecstasy) caffeine; cocaine; medical diagnosis of drug abuse; management of selected problems (overdose, withdrawal, treatment of new born infants); drug abuse and the law. The use of each drug is described together with its social and clinical effects. Process Validation. 2nd Edition-Edited by I. R. BERRYand R. A. NASH. 597 pp. 1993. Marcel Dekker, New York. $125.
6th Edition-Edited by H. P. and F. W. O’GRADY. 561 DD. 1992. Churchill Livingstone, Edinburgh, $149.95.
Pharmaceutical
This major text has been completely revised and brought up to date. The chapters deal with (1) agents; aminoglycosides and aminocyclitols; antifungals; antimycobacteria; antivirals; beta lactams; cephalosporins; chloramphenicol and thiamphenicol; coumarins; cycloserine; diamidines; diaminopyridines; fosfomycin and fosmidomycin; fusidanes; hexamine; lincosamides; macrolides; mupirocin; nitrofurans; nitroimidazoles; penicillins; peptides; quinolones; rifamycins; sulphonamides; tetracychnes; mode of action; bacterial resistance. (2) Treatment; general principles; immunocomprised host; infective endocarditis; septicaemia; respiratory tract; meningitis; alimentary tract; bacterial skin; urinary tract; obstetrics; sexually transmitted diseases; eye; tuberculosis and leprosy; renal failure; chemoprophylaxis. In dealing with each drug the chapter gives its structure; antimicrobial activity; acquired resistance; pharmacokinetics; toxicity and side effects; clinical use; preparations and dosage; references. A very useful book.
The previous edition came out 8 years ago and in 1987 the FDA produced their Guidelines on the general principles of process validation. There is also the development of current good manufacturing practice regulations. This new edition reflects the care that has to be taken over these new requirements. It deals with the validation (V) of; sterile products; solid dosage forms; quality assurance; prospective process V; retrospective process V; V of water systems; cleaning V; equipment V; process V of raw materials; V of analytical methods; V of computer systems; V of lyophilized products; V of inhalation aerosols; use of quality control charts; multivariate graphical analysis; new trends in process V; V terminology. When billions of doses of drugs are consumed by the public, the validation of the procedures producing these drugs has to be of a very high standard otherwise the mortician gets the patient and the lawyers get the manufacturer.
Antibiotic and Chemotherapy. LAMBERT
New Approaches in Cancer Pharmacology; Drug Design and Development-Edited by P. WORKMAN. 103 pp. 1992. Springer, Berlin. DM 102. With the increase in understanding the basic biology of cell reproduction, has come a greater understanding of the control methods. This is reflected in the present volume which deals with; sequence and gene specific drugs; antisense and antigene oligonucleotides targeted to oncogenes; biological and gene therapies; membrane and signal transduction targets; novel anti-endocrine agents; bioreductive drugs [hypoxia]; therapeutic drug monitoring and dose optimization in oncology; current strategies of anticancer drug discovery, i.e. targeting onto cell membrane; growth factors and receptors; signal tranduction proteins; oncogenes; cell cycle regulators; extrachromosomal DNA; hypoxia; tumour cell differentiation; tumour vasculature; topiosomerase I; mitochondria; microtubules.
New Drug Approval Process. 2nd Edition-Edited by R. A. GUARINO.469~~. 1993. Marcel Dekker, New York. $150 ($65 if 5 or more copies are bought for classroom use). This new edition has been revised and updated to reflect the current rules, regulations and guidelines of Title 21 of the Code of Federal Regulations. The topics dealt with are; non-clinical research evaluation; Investigational New Drug (IND) and clinical investigators brochure; clinical research protocols; clinical development of OTC drugs; statistical and data management collaboration in clinical research; biotechnology; image processing techniques applied to drug development; obligations of investigator, sponsor and monitor; management of clinical studies; adverse reactions and interactions of drugs; institution review boards, informed consent and auditing; new drug application (NDA); drug product labelling; drugs for life threatening diseases; abbreviated and supplemental new drug applications; the orphan drugs. This book should help the investigator through the administration minefields.